Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) gained volume of 1.97 million shares and the average volume of the stock remained 1.51 million shares. The 52 week range of the stock remained $1.48 – $11.84 and today’s day range was $11.07 – $11.64. The stock opened the session at $11.60 but then moved to $11.07, at recent check. At that price, the stock was showing a negative performance of -4.98%.
Arrowhead Pharmaceuticals, Inc. (ARWR) on May 30, 2018 announced that it has completed enrollment and dosing of all 5 planned cohorts of healthy adult volunteers in the single-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection. The company intends to submit a late-breaking abstract with initial clinical data on ARO-HBV to the Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held in November.
AROHBV1001 (NCT03365947) is a Phase 1/2 study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, and evaluating the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of ARO-HBV in patients with chronic HBV.
Joey New York, Inc. (OTCBB:JOEY) was trading with a volume of 29,252.00 shares versus the average volume of the stock 26,858.00 shares. The stock increased +18.89% and was recently trading at $0.107. The market capitalization of the stock remained 3.36 million.
Joey New York, Inc., through its subsidiary, RAR Beauty, LLC, manufactures and markets natural skin care and beauty products in the United States and Internationally. The company operates through The LABB, Aesthetic Beauty Bar; and Joey New York Cosmetics divisions. The LABB, Aesthetic Beauty Bar division provides injectable services, which eliminate unwanted wrinkles by performing Botox and filler injections. The company offers its products under the Joey New York brand. It offers its products through retailers, professional salons, spas, and beauty Websites.
In the current trading day, Athenex, Inc. (NASDAQ:ATNX) increased +4.13% to move at $18.65. The volume of the stock was 1.1 million shares and the average volume remained 267.26K shares. The stock, at last check, has the day price range of $17.74 – $18.86. The market capitalization was recorded at 1.21 billion.
Athenex, Inc. (ATNX) on June 15, 2018 announced the appointment of Benson Tsang to the Board of Directors, effective July 1, 2018. Mr. Tsang will serve as the Chairman of the Audit and Risk Management Committee as well as a member of the Nominating and Corporate Governance Committee.
Mr. Tsang brings over 30 years of financial and general management experience to Athenex. He currently provides financial and operational advisory services through his consultancy firm to clients in the USA, Canada and China. Mr. Tsang previously held the role of Chief Financial Officer of WuXi Pharmatech Inc. where he played a crucial role in the company’s successful IPO in 2007, and served as an independent director of Shangpharma Corp. Mr. Tsang has also held senior positions at ATA Inc., PCCW Ltd., Imation Corp., Coopers & Lybrand and Deloitte. He is a member of the Chartered Professional Accountants of Canada and the Hong Kong Institute of Certified Public Accountants. Mr. Tsang holds a Bachelor of Commerce degree and an MBA from McMaster University in Ontario, Canada.